MEDDIC vs Challenger for M&A Advisors Selling on Timing
A founder decides to transact for reasons that usually have nothing to do with the last conversation you had with them, a health scare, a partner wanting out, a competitor's acquisition offer landing in their inbox unprompted. Importing MEDDIC's forecast discipline onto that kind of decision, expecting a tidy timeline because a milestone was hit, is the standard mistake in M&A advisory and growth strategy sales.
The framework earns its keep somewhere else entirely: catching the sell-side conversation where no board has actually agreed to run a process yet. Challenger is how that conversation starts a year earlier than it otherwise would, and the two approaches genuinely serve different moments in the same relationship.
Vendors Covered in this Article
Disclosure: We may earn a commission if you buy through some links on this page. It doesn't change what we recommend.
The Approach That Assumes a Trigger Already Exists
Standard sales qualification assumes a prospect has already decided to act and is choosing among vendors. Applied to M&A advisory, that means only engaging once a board has voted to explore a sale or a founder has explicitly said they're ready, which is often too late to shape the process meaningfully. By the time a formal mandate exists, other advisors are usually already in the room, and your firm is competing on credentials rather than on the relationship you could have built earlier.
This reactive posture isn't wrong, exactly, it's just incomplete. A firm that only pursues mandates once a trigger has already occurred will always be one of several advisors a founder is evaluating, competing on reputation and fee rather than on a relationship built before the decision was made.
The Approach That Creates the Trigger Earlier
Instead of waiting for a founder to decide, a Challenger-style advisor introduces a reframe well before any formal process: pointing out that a specific competitor's recent acquisition changes the buyer landscape for a founder's own eventual exit, or that a market window for their sector's multiples may be narrowing. Done credibly, this can move a founder's timeline forward by a year or more, provided the insight is specific to their situation rather than a generic pitch about market conditions that could apply to any company.
The risk runs the other way too: a founder who feels pushed toward a decision they weren't ready for will remember that pressure, even if they eventually do transact with a different advisor entirely. The reframe has to genuinely serve the founder's interests, not just create urgency for its own sake, or it damages the relationship it was meant to build.
What makes a proactive reframe credible to a founder:
- It points to something specific, such as a competitor's recent acquisition changing the buyer landscape for the founder's own eventual exit.
- It flags a market window for the sector's multiples that may be narrowing, backed by real sector expertise.
- It accepts that not every reframe lands, since the approach requires a willingness to be wrong sometimes.
The Tradeoff Between the Two
Waiting for a trigger is lower effort per pursuit but concedes the earliest, most relationship-driven part of the sale to whichever advisor got there first. Creating a trigger requires real sector expertise and a willingness to be wrong sometimes, since not every reframe lands, but it's the only path to being the advisor a founder thinks of first when a real event eventually does occur. Most established M&A practices end up running both simultaneously: reactive coverage of known active mandates alongside proactive relationship-building with founders who haven't decided yet.
How a firm splits partner time between the two usually reflects how mature its proactive muscle already is. A younger practice without deep sector relationships often has little choice but to lean reactive at first, while a firm with a longer track record in a specific sector can afford to invest more heavily in the proactive side, since its reframes carry more credibility from the start.
Building Pipeline Coverage for a Category With No Fixed Cycle
A 3x to 4x pipeline coverage ratio assumes a fairly predictable win rate and cycle length1, which doesn't describe M&A advisory well, since a proactive relationship can sit dormant for years before a trigger event activates it. Track proactive relationships separately from active mandates in your pipeline reporting, since blending a long list of dormant relationships with a handful of live mandates produces a coverage number that means very little on its own.
What a Missed Mandate Target Actually Reflects
Only 51 percent of B2B sellers hit their number in a typical year2, and for an M&A practice, a miss usually traces back to a pipeline overweighted with reactive relationship management and underweighted with the proactive work that generates a mandate before a competing advisor gets there first. A partner whose forecast leans entirely on inbound inquiries is exposed to exactly the unpredictability that makes this category harder to plan than most.
The fix isn't to abandon reactive work, since inbound mandates are real revenue and shouldn't be deprioritized. It's to hold partners accountable for a minimum amount of proactive sector development alongside whatever reactive mandates happen to land in a given year, so the firm's growth doesn't depend entirely on which founders happen to call first.
What Good Looks Like
A well run M&A advisory practice tracks proactive founder relationships separately from active mandates, and can point to specific, credible triggers, not generic market conditions, behind every mandate it originated proactively.
Building The Capability (5-Stage Skill Ladder)
How to Get Started
Disclosure: We may earn a commission if you buy through some links on this page. It doesn't change what we recommend.
Frequently Asked Questions
How do we know if a proactive reframe is credible or just noise to a founder?
It has to reference something specific to their company or sector, not a generic market observation any advisor could make. A founder can usually tell the difference between an advisor who's done real work understanding their situation and one running the same pitch on everyone in a sector list.
Is it worth maintaining relationships with founders who show no interest in selling?
Selectively, yes, particularly in sectors where you have genuine expertise and can add value through market intelligence even without an active mandate. Maintaining hundreds of low-value relationships isn't worthwhile, but a focused list where you're a credible sector voice pays off when a trigger eventually does occur.
How should partner compensation account for this kind of unpredictable cycle?
Credit partners for both proactive relationship development and closed mandates, not closed deals alone. Compensation based purely on closed deals pushes partners toward chasing only active, visible processes and neglecting the longer term relationship work that generates future mandates, so a blended structure tends to hold up better.
What's a reasonable way to forecast a pipeline this unpredictable?
Separate active mandates, where a real process is underway, from proactive relationships, where no trigger has occurred yet, and forecast only against the first category with any real confidence. Treat the second category as a leading indicator of future pipeline health rather than as revenue you can currently count on.
Sources
Where we quote a benchmark, we show its source. Other figures in this guide are estimates or general guidance, so check them against your own numbers.
- Pipeline coverage ratio norms. Clari — Pipeline Coverage Ratio best practices, 2025.
- Percent of SaaS AEs hitting quota (Bridge Group). The Bridge Group 2024 SaaS AE Metrics & Compensation Report, 2024.
Related Guides
MEDDIC vs Challenger Sale vs SPIN Selling: Enterprise Sales Frameworks
Compare MEDDIC, Challenger Sale, and SPIN Selling for B2B enterprise sales: deal qualification, buying committees, discount protection, and win rates.
Winning Consulting Engagements Without an RFP to Hide Behind
Consulting engagements rarely follow a software buying process. Here is how MEDDIC's qualification discipline and Challenger's teaching each translate.
MEDDIC vs Challenger When the Blocker Is a Warehouse Login
A client asks for a dashboard when the real problem is a definitions fight. Here's a runbook for using MEDDIC and Challenger in data consulting deals.
Splitting Success Fees Across an M&A Deal Team
Success fees land in lumps, months apart, split among an originator, a deal lead, and an analyst. Here is how to model that split, and which tool fits.
Apollo vs ZoomInfo for M&A Advisory and Growth Strategy Firms
Private-company data is the real test for an M&A advisory or growth strategy practice. Here's how Apollo and ZoomInfo compare on ownership and revenue signals.
Recording Calls on Live M&A and Growth Strategy Deals
A checklist for M&A advisory and growth strategy firms on whether and how to record deal calls with Fathom or Fireflies without breaking confidentiality.